Drug Trial Radar · NCT06015308
A Study to Investigate Vaccine Responses in Subcutaneous Amlitelimab Treated Atopic Dermatitis Participants Aged 18 Years and Older Compared With Placebo
Last checked: Nov 20, 2026Latest source record: Aug 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
224
Actual
Start
Oct 6, 2023
Primary completion
Oct 1, 2025
Study completion Jan 16, 2026
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- First posted
- Aug 29, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 2, multicenter, randomized, double-blind placebo controlled, 2-arm study to evaluate the effect of amlitelimab on vaccine antibody responses, and the safety of amlitelimab concurrently administered with non-live vaccines in adult participants with moderate-to-severe atopic dermatitis (AD). The purpose of this study is to compare the immune responses to concomitantly administered Boostrix (tetanus, diphtheria, and acellular pertussis \[Tdap\]) and Pneumovax 23 (PPSV) vaccines in adult participants with moderate-to-severe AD treated with amlitelimab versus placebo. The study will evaluate the percentage of participants achieving a positive anti-tetanus response at Week 16 (primary endpoint) and a positive anti-pneumococcal response at Week 16 (key secondary endpoint). Study details include: The study duration will be up to 36 weeks (for participants not entering the LTS17367 \[RIVER-AD\]). The screening period will be 9 days to 4 weeks. The treatment duration will be up to 16 weeks. The post-treatment safety follow-up period will be16 weeks. The number of visits will be up to 7 (or 6 for those entering LTS17367 \[RIVER-AD\]).
Conditions
- Dermatitis Atopic
Interventions
AmlitelimabDrug
Subcutaneous injection in abdomen, outer thigh, or upper arm
PlaceboDrug
Subcutaneous injection in abdomen, outer thigh, or upper arm
Tdap vaccineBiological
Intramuscular (IM) injection into the deltoid muscle of the upper arm
PPS vaccineBiological
Intramuscular or subcutaneous injection into the deltoid muscle of the upper arm
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of participants with a positive tetanus response at Week 16Time frame: Week 16
Locations
57 sites in 2 countries. Site status is shown where the registry gives one.
Clinical Research Center of Alabama - Homewood- Site Number : 8401101
Birmingham, Alabama
Center for Dermatology and Plastic Surgery- Site Number : 8401119
Scottsdale, Arizona
Orange County Clinical Trials- Site Number : 8401271
Anaheim, California
First OC Dermatology- Site Number : 8401025
Fountain Valley, California
Center for Dermatology Clinical Research- Site Number : 8401018
Fremont, California
Valley Research- Site Number : 8401097
Fresno, California
Paradigm Clinical Research Centers- Site Number : 8401273
La Mesa, California
Sunwise Clinical Research- Site Number : 8401022
Lafayette, California
Antelope Valley Clinical Trials- Site Number : 8401099
Lancaster, California
Torrance Clinical Research- Site Number : 8401027
Lomita, California
Clinical Science Institute- Site Number : 8401028
Santa Monica, California
Velocity Clinical Research - Denver Site Number : 8401168
Denver, Colorado
Daxia Trials- Site Number : 8401145
Boca Raton, Florida
Encore Medical Research of Boynton Beach- Site Number : 8401030
Boynton Beach, Florida
Alliance for Multispeciality Research - Fort Myers- Site Number : 8401111
Fort Myers, Florida
Doral Medical Research- Site Number : 8401094
Hialeah, Florida
C&R Research Services - Kendall- Site Number : 8401029
Kendall, Florida
Acevedo Clinical Research Associates- Site Number : 8401088
Miami, Florida
Future Care Solution - Miami- Site Number : 8401144
Miami, Florida
Sanchez Clinical Research- Site Number : 8401095
Miami, Florida
Florida International Research Center- Site Number : 8401091
Miami, Florida
Wellness Clinical Research - Miami Lakes- Site Number : 8401109
Miami Lakes, Florida
K2 South Orlando - South Orange Avenue- Site Number : 8401268
Orlando, Florida
SEC Clinical Research- Site Number : 8401270
Pensacola, Florida
Global Clinical Professionals (GCP)- Site Number : 8401045
St. Petersburg, Florida
Clinical Research Trials of Florida- Site Number : 8401023
Tampa, Florida
Paradigm Clinical Research - Boise- Site Number : 8401272
Boise, Idaho
Skin Sciences- Site Number : 8401039
Louisville, Kentucky
Velocity Clinical Research at The Dermatology Clinic- Site Number : 8401072
Baton Rouge, Louisiana
BRCR Global Gretna- Site Number : 8401243
Gretna, Louisiana
Boeson Research - Missoula- Site Number : 8401269
Missoula, Montana
Henderson Clinical Trials- Site Number : 8401169
Henderson, Nevada
Skin Search Rochester- Site Number : 8401216
Rochester, New York
Velocity Clinical Research - Durham- Site Number : 8401175
Durham, North Carolina
Velocity Clinical Research - Springdale- Site Number : 8401153
Cincinnati, Ohio
Velocity Clinical Research - Medford- Site Number : 8401170
Medford, Oregon
Vial Health - DermDox Dermatology- Site Number : 8401031
Camp Hill, Pennsylvania
Velocity Clinical Research - Providence- Site Number : 8401179
East Greenwich, Rhode Island
Velocity Clinical Research - Charleston - Ashley Town Center Drive- Site Number : 8401174
Charleston, South Carolina
Velocity Clinical Research - Columbia- Site Number : 8401176
Columbia, South Carolina
Showing 40 of 57 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.